Sinphar Pharmaceutical Co.,Ltd. - Laporan Laba Rugi (TTM)

Sinphar Pharmaceutical Co.,Ltd.
TW ˙ TWSE ˙ TW0001734002
NT$ 31.45 ↓ -0.10 (-0.32%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Sinphar Pharmaceutical Co.,Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 2,520 2,388 2,380 2,405 2,333 2,434 2,485 2,593 2,735 2,857 2,959 2,970 2,977 2,963 2,969 3,011 3,045 3,151 3,179 3,222
Change (%) -5.20 -0.36 1.06 -3.02 4.32 2.14 4.34 5.48 4.43 3.58 0.38 0.22 -0.47 0.22 1.41 1.12 3.48 0.89 1.37
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,528 1,513 1,545 1,568 1,511 1,545 1,543 1,593 1,679 1,764 1,839 1,891 1,894 1,869 1,844 1,833 1,870 1,910 1,912 1,907
Change (%) -0.99 2.12 1.49 -3.62 2.22 -0.09 3.24 5.35 5.09 4.25 2.84 0.12 -1.29 -1.33 -0.58 1.98 2.18 0.07 -0.22
% of Revenue 60.65 63.34 64.92 65.19 64.79 63.48 62.10 61.44 61.37 61.75 62.15 63.67 63.61 63.08 62.10 60.89 61.40 60.63 60.13 59.19
Gross Operating Profit 991 876 835 837 821 889 942 1,000 1,057 1,093 1,120 1,079 1,083 1,094 1,125 1,178 1,175 1,240 1,267 1,315
Change (%) -11.69 -4.64 0.27 -1.88 8.19 6.01 6.14 5.69 3.38 2.49 -3.65 0.41 0.98 2.86 4.66 -0.21 5.54 2.17 3.77
% of Revenue 39.35 36.66 35.08 34.81 35.21 36.52 37.90 38.56 38.63 38.25 37.85 36.33 36.39 36.92 37.90 39.11 38.60 39.37 39.87 40.81
SG&A 531 535 536 537 538 560 571 583 599 622 635 658 668 673 723 739 757 792 791 816
Change (%) 0.74 0.08 0.27 0.12 4.04 1.99 2.11 2.78 3.80 2.13 3.63 1.46 0.74 7.47 2.28 2.35 4.64 -0.04 3.15
% of Revenue 21.09 22.41 22.51 22.34 23.06 23.00 22.96 22.47 21.90 21.77 21.46 22.16 22.43 22.70 24.34 24.55 24.85 25.13 24.90 25.34
R&D 494 462 447 420 537 512 479 440 254 272 260 254 260 133 128 116 97 151 141 142
Change (%) -6.47 -3.24 -6.17 27.85 -4.63 -6.34 -8.25 -42.34 7.31 -4.52 -2.44 2.53 -48.99 -3.45 -9.29 -16.47 56.07 -7.07 0.76
% of Revenue 19.62 19.36 18.80 17.45 23.01 21.03 19.29 16.96 9.27 9.53 8.78 8.54 8.73 4.47 4.31 3.86 3.19 4.80 4.42 4.40
OpEx 2,554 2,511 2,528 2,525 2,586 2,616 2,594 2,616 2,531 2,658 2,734 2,803 2,821 2,674 2,695 2,689 2,723 2,853 2,844 2,866
Change (%) -1.69 0.70 -0.12 2.41 1.18 -0.87 0.87 -3.24 5.01 2.86 2.52 0.65 -5.21 0.77 -0.23 1.28 4.78 -0.34 0.77
% of Revenue 101.37 105.12 106.23 104.98 110.85 107.51 104.35 100.88 92.53 93.05 92.40 94.37 94.77 90.25 90.76 89.30 89.44 90.57 89.46 88.93
Operating Income -34 -122 -148 -120 -253 -183 -108 -23 204 199 225 167 156 289 274 322 322 297 335 357
Change (%) 255.09 21.34 -19.16 111.21 -27.81 -40.86 -78.96 -997.81 -2.73 13.24 -25.60 -6.93 85.38 -4.96 17.44 -0.22 -7.58 12.77 6.50
% of Revenue -1.37 -5.12 -6.23 -4.98 -10.85 -7.51 -4.35 -0.88 7.47 6.95 7.60 5.63 5.23 9.75 9.24 10.70 10.56 9.43 10.54 11.07
Interest Expense -25 -25 -25 -24 -24 -25 -24 -25 -26 -28 -30 -32 -33 -34 -34 -35 -36 -37 -37 -36
Change (%) -0.89 0.35 -0.86 0.29 1.39 -1.58 3.39 3.82 6.16 9.02 4.00 3.41 3.38 1.75 2.91 2.62 1.50 0.27 -1.25
% of Revenue -0.98 -1.03 -1.03 -1.01 -1.05 -1.02 -0.98 -0.97 -0.96 -0.97 -1.02 -1.06 -1.10 -1.14 -1.16 -1.17 -1.19 -1.17 -1.16 -1.13
Net Income 60 -29 -50 -53 -77 -38 15 97 198 225 247 268 277 375 405 361 333 305 307 310
Change (%) -147.27 76.24 6.44 44.27 -50.57 -139.14 548.70 104.85 13.26 9.80 8.85 3.01 35.64 8.07 -10.88 -7.90 -8.44 0.66 1.02
% of Revenue 2.39 -1.19 -2.11 -2.22 -3.31 -1.57 0.60 3.73 7.25 7.86 8.34 9.04 9.29 12.66 13.65 12.00 10.93 9.67 9.65 9.61

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista